Meghan Chan
Psychiatry · Flushing, NYNPI 1639243546
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 257 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 20.5% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 257 payments — averaging $45.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Alkermes, Inc.$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$999
- plus $3K from 12 others
What the payments were for
- Food & beverage$11,676100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 43 | $2,396 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 52 | $1,714 |
| Alkermes, Inc. | 26 | $1,361 |
| Otsuka America Pharmaceutical, Inc. | 15 | $1,071 |
| Neurocrine Biosciences, Inc. | 21 | $1,010 |
| Teva Pharmaceuticals USA, Inc. | 21 | $999 |
| Axsome Therapeutics, Inc. | 7 | $683 |
| E.r. Squibb & Sons, L.L.C. | 8 | $682 |
| Sunovion Pharmaceuticals Inc. | 27 | $518 |
| Johnson & Johnson | 3 | $373 |
| Idorsia Pharmaceuticals US Inc | 6 | $197 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $196 |
| Supernus Pharmaceuticals, Inc. | 5 | $179 |
| Vanda Pharmaceuticals Inc. | 1 | $116 |
| Corium, LLC | 6 | $103 |
| Neuronetics, Inc. | 2 | $44 |
| Lundbeck LLC | 1 | $26 |
| Indivior Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$2,372
- VRAYLAR$1,731
- ARISTADA$1,000
- CAPLYTA$927
- Auvelity$627
- INGREZZA$609
- REXULTI$603
- COBENFY$508
- SPRAVATO$373
- UZEDY$352
- ARISTADA INITIO$250
- LATUDA$245
- Austedo XR$125
- AUSTEDO$125
- ABILIFY ASIMTUFII$125
- ABILIFY MAINTENA$125
- QELBREE$125
- QUVIVIQ$121
- Fanapt$116
How this compares
$11,689 in reported general payments places this provider in the 95th percentile of 3,713 psychiatry providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $91,830 |
| VraylarCariprazine Hcl | 20 | $27,983 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,914 |
| VascepaIcosapent Ethyl | 25 | $4,602 |
| BelsomraSuvorexant | 11 | $4,389 |
| Duloxetine Hcl | 28 | $1,537 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 28 | $1,255 |
| Mirtazapine | 79 | $1,176 |
| Divalproex Sodium ErDivalproex Sodium | 29 | $918 |
| Omega-3 Acid Ethyl Esters | 16 | $845 |
| AmantadineAmantadine Hcl | 19 | $589 |
| Olanzapine | 76 | $588 |
| Aripiprazole | 62 | $587 |
| Escitalopram Oxalate | 101 | $574 |
| Quetiapine Fumarate | 71 | $555 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,010 | $91,83011 claims |
| AbbVieVraylar | $2,396 | $27,98320 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $196 | $5,91412 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,713 psychiatry providers in New York.
Other psychiatry in Flushing
- Leslie CitromePomona$5.7M
- Sanjay GuptaCheektowaga$1.9M
- Richard PriceMonsey$1.7M
- Adam AshtonAmherst$1.6M
- Christoph CorrellGlen Oaks$1.5M
- Manish ZinzuvadiaNew York$1.3M
- George KruseBronx$1.2M
- Jianping ChenNew York$1.2M
- Horacio CapoteAmherst$1.1M
- Yadagiri ChepuruYonkers$963K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.